nivolumab,ipilimumab
bms
['gu ', 'nivolumab', 'hcrn,gu16,260', 'hcrn,gu,16,260', 'rcc,(-irccs),(-srcc),(-urcc)', ' ipi ', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ca209,669', 'nivo', 'bms']
treatment-free survival outcomes from the phase ii study of nivolumab and salvage nivo + ipi in adv clear cell #rcc (hcrn gu16-260-cohort a). presented by michael atkins, md . #gu23 coverage &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology